Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Russian Multicenter Clinical Trial

Bondarenko, SN; En, Parovichnikova; Maschan, A.; Баранова, О Ю; Shelekhova, TV; Doronin, VA; Mel’nichenko, VYa; Kaplanov, KD; Uspenskaya, OS; Sokolov, A N; Myakova, NV; Моисеев, И. С.; Markova, IV; Darskaya, Elena I.; Smirnova, AG; Быкова, Т А; Ayubova, Bella; Самородова, И А; Бабенко, Е В; Barkhatov, I. M.; Гиндина, Т. Л.; Афанасьев, Б. В.; str., Saint Petersburg L’va Tolstogo; Immunology, Samory Mashela str.; Dispensary, Zemlyachki str. Volgograd Regional Clinical Oncologic

doi:10.21320/2500-2139-2019-12-2-145-153

Cited by 5 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Blinatumomab is a bispecifi c T-cell engager (BiTE) antibody designed to link T cells and CD19-positive B cells, which allows the patient's endogenous T cells to recognize and eliminate CD19-positive ALL blasts [8]. Blinotumomab is highly eff ective in R/R ALL patients with 69% of complete remission (CR), or with incomplete hematologic recovery achieved even aft er alloHSCT [4,[9][10]. Jabbour et al reported 68 patients with R/R B-cell ALL with blinatumomab failure, 38 (56%) of them was initially refractory to this treatment [11].…”

Section: Discussionmentioning

confidence: 99%

Successful treatment of relapsed/refractory B-Acute lymphoblastic leukemia with Inotuzumab ozogamicin after blinatumomab failure

Bondarenko

Smirnova

Moiseev

et al. 2020

CTT

View full text Add to dashboard Cite

Blinatumomab, a bispecific T-cell engaging CD3-CD19 antibody, is highly effective in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) even after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, patients who failed with Blina have a dismal outcome. Inotuzumab ozogamicin is one of the therapeutic options after blinatumomab failure. We report a young man who exhibited bone marrow (BM) relapse of B-ALL following haploidentical stem cell transplantation (haplo-HSCT). Remission was not achieved after Blinotumomab treatment, thus Inotuzumab was administered. A complete remission with no signs of minimal residual disease was achieved after a single cycle of Inotuzumab. The second haplo-HSCT from another donor was successful. Conclusion The present case demonstrate an opportunity of successful inotuzumab therapy after failure of allo-HSCT and blinotumomab treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful treatment of relapsed/refractory B-Acute lymphoblastic leukemia with Inotuzumab ozogamicin after blinatumomab failure

Bondarenko

Smirnova

Moiseev

et al. 2020

CTT

View full text Add to dashboard Cite

show abstract

“…Blinotumomab is highly effective in R/R ALL patients with 69% of complete remission or complete remission with incomplete hematologic recovery achieved even after allo-HSCT [7][8][9]. In TOWER study the 1-year, the overall survival (OS) rate was 36% (median OS, 7.7 months), and the duration of remission was 7.3 months.…”

Section: Discussionmentioning

confidence: 99%

Successful treatment of extramedullary relapsed/refractory B-acute lymphoblastic leukemia with Inotuzumab ozogamicin before and after allogeneic stem cell transplantation

Smirnova¹,

Bondarenko²,

Moiseev³

et al. 2019

CTT

View full text Add to dashboard Cite

Recent advances in treatment of relapsed/refractory B-Acute Lymphoblastic Leukemia (R/R BALL) are associated with targeted immune therapies, such as Blinatumomab, Inotuzumab ozogamicin and CART cells. Several clinical studies demonstrate superior complete remission (CR) and allogeneic stem cell transplantation (allo-HSCT) rates after Blinatumomab or Inotuzumab treatment compared to conventional chemotherapy with different toxicity profiles. However, treatment of extramedullar lesions was not addressed in these trials. Case presentation We report two R/R BALL patients with extramedullar involvement. Case 1. A woman, 31 years old with Philadelphia positive BALL , being in second relapse not responding to Blinotumomab. Clinical progression was observed, with involvement of bone marrow (BM), cervical, mandibular lymph nodes and breast lesions. Complete BM and extramedullary remission was achieved after Inotuzumab followed by allogeneic stem cell transplantation from a matched related donor was performed. Case 2. A 25 years-old young woman exhibited a BM relapse after unrelated stem cell transplantation. Remission was achieved after Blinotumomab treatment. Inotuzumab was administered for 6th extramedullary relapse. A complete metabolic response was achieved after 4 cycles of Inotuzumab as shown by PET scanning. Conclusion The present cases demonstrate an opportunity for Inotuzumab administration after Blinotumomab failure in case of extramedullary relapse before and after allo-HSCT.

show abstract

Use of Blinatumomab in Acute Lymphoblastic Leukemia in Municipal Healthcare: A Case Report

Shuvaev

Ushakova

Mullo

et al. 2021

Клиническая онкогематология

View full text Add to dashboard Cite

Acute lymphoblastic leukemia is one of the groups of most challenging malignant neoplasms of hematopoietic tissue. Despite the success in achieving remission induction in primary patients, later, most of them develop disease relapses. Overall and disease-free survivals have to be improved, which cannot be achieved solely with chemotherapy intensification. The new target drugs and cell technologies improve the treatment options for the resistant forms and relapses of acute lymphoblastic leukemia. The effective use of new drugs presupposes their timely assignment which can be ensured by their availability in routine clinical practice. The provided case report describes the successful use of bispecific antibody blinatumomab for treating an early relapse of acute lymphoblastic leukemia in the clinical practice within the municipal healthcare system.

show abstract

Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Russian Multicenter Clinical Trial

Cited by 5 publications

References 14 publications

Successful treatment of relapsed/refractory B-Acute lymphoblastic leukemia with Inotuzumab ozogamicin after blinatumomab failure

Successful treatment of relapsed/refractory B-Acute lymphoblastic leukemia with Inotuzumab ozogamicin after blinatumomab failure

Successful treatment of extramedullary relapsed/refractory B-acute lymphoblastic leukemia with Inotuzumab ozogamicin before and after allogeneic stem cell transplantation

Use of Blinatumomab in Acute Lymphoblastic Leukemia in Municipal Healthcare: A Case Report

Contact Info

Product

Resources

About